1. The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19
- Author
-
Campos Varela, Isabel, Villagrasa, Ares, Simon-Talero, Macarena, Riveiro Barciela, Mar, Ventura-Cots, Meritxell, Aguilera-Castro, Lara, Álvarez-López, Patricia, Nordahl, Emilie A., Anton, Adrian, Bañares, Juan, Barber, Claudia, Barreira-Diaz, Ana, Biagetti, Betina, Camps-Relats, Laura, Ciudin, Andreea, Cocera, Raul, Dopazo, Cristina, Fernandez, Andrea, Jiménez, Cesar, Jiménez, María M., Jofra, Mariona, Gil, Clara, Gómez Gavara, Concepción, Guanozzi, Danila, Guevara, Jorge A., Lobo, Beatriz, Malagelada Prats, Carolina, Martinez-Camprecios, Joan, Mayorga, Luis, Miret Alomar, Enric, Pando, Elizabeth, Pérez-Lopez, Ana, Pigrau Pastor, Marc, Prio, Alba, Rivera-Esteban, Jesus M., Romero, Alba, Tasayco, Staphanie, Vidal-Gonzalez, Judit, Vidal, Laura, Minguez, Beatriz, Augustin Recio, Salvador, Genescà, J., Universitat Autònoma de Barcelona, Institut Català de la Salut, [Campos-Varela I, Augustin S] Unitat del Fetge, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Villagrasa A, Alvarez-Lopez P, Anton A, Bañares J, Barreira-Diaz A, Camps-Relats L, Jimenez C, Gil C, Martinez-Camprecios J, Prio A, Rivera-Esteban JM, Romero A, Vidal-Gonzalez J] Unitat del Fetge, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Simon-Talero M, Riveiro-Barciela M, Ventura-Cots M, Minguez B, Genesca J] Unitat del Fetge, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. [Aguilera-Castro L, Barber C, Guanozzi D, Lobo B, Malagelada C, Mayorga L, Tasayco S] Servei de l’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Nordahl EA] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Biagetti B, Ciudin A] Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Cocera R, Miret E] Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Dopazo C, Fernandez A, Jofra M, Gomez-Gavara C, Pando E, Vidal L] Servei de Cirurgia Hepatobiliopancreàtica i Trasplantaments, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Jimenez MM, Pérez-Lopez A] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Gomez-Gavara C, Pigrau M] Servei d’Endoscòpia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,ALT ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,RC799-869 ,Liver injury ,Gastroenterology ,Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores] ,Liver disease ,Liver steatosis ,Internal medicine ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,Medicine ,In patient ,AST ,Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] ,COVID-19 (Malaltia) - Complicacions ,Original Research ,business.industry ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] ,Diseases of the digestive system. Gastroenterology ,medicine.disease ,CAP ,controlled attenuation parameter ,enfermedades del sistema digestivo::enfermedades hepáticas [ENFERMEDADES] ,Fetge - Malalties - Imatgeria ,Digestive System Diseases::Liver Diseases [DISEASES] ,Controlled attenuation parameter ,business ,Transient elastography ,Other subheadings::Other subheadings::/complications [Other subheadings] ,liver injury - Abstract
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Paràmetre d'atenuació controlat; Lesió hepàtica Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Parámetro de atenuación controlado; Daño hepático Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Controlled attenuation parameter; Liver injury Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level > 50 U/ml at admission had a significantly higher risk of ICU and/or death than those with AST ⩽ 50 U/ml (50% versus 13.3%, p
- Published
- 2021